Bayer AG

DB:BAYN

德國 / 保健 / 製藥

綜觀

股息

10年歷史財務資料

股價

22.66 EUR


Key Metrics	Latest
Total Revenue	46.606 B
Adjusted EBITDA	9.139 B
EBITDA Margin	19.6%
Net Profit Margin	3.3%
Total Assets	110.8 B
Total Debt	40.811 B

10Y Historical Financial Statements

Summary Financials


Summary Financials

	Fiscal Year Ending										Latest
(in millions)	Dec-15	Dec-16	Dec-17	Dec-18	Dec-19	Dec-20	Dec-21	Dec-22	Dec-23	Dec-24	12 Months

Revenue	46,085	34,943	35,015	36,742	43,545	41,400	44,081	50,739	47,637	46,606	46,606
% Growth		-24.2%	0.2%	4.9%	18.5%	-4.9%	6.5%	15.1%	-6.1%	-2.2%

Adjusted EBITDA	9,877	8,915	8,995	7,145	10,810	10,030	10,877	12,705	11,331	9,139	9,139
% Margin	21.4%	25.5%	25.7%	19.4%	24.8%	24.2%	24.7%	25.0%	23.8%	19.6%	19.6%

Adjusted EBIT	6,773	6,557	6,875	4,257	6,980	6,972	7,475	9,121	7,799	5,448	5,448
% Margin	14.7%	18.8%	19.6%	11.6%	16.0%	16.8%	17.0%	18.0%	16.4%	11.7%	11.7%

Adjusted Net Income	4,680	5,322	8,344	2,727	6,291	6,321	4,092	5,838	2,385	1,558	1,558
% Margin	10.2%	15.2%	23.8%	7.4%	14.4%	15.3%	9.3%	11.5%	5.0%	3.3%	3.3%

Adjusted Basic EPS	5.66	6.39	9.57	2.90	6.41	6.43	4.16	5.94	2.43	1.59	1.59

支援算式

Income Statement

Balance Sheet

Statement of Cashflows


Income Statement
											Reclassified
EUR	Fiscal Year Ending										Latest
(in millions)	Dec-15	Dec-16	Dec-17	Dec-18	Dec-19	Dec-20	Dec-21	Dec-22	Dec-23	Dec-24	Dec-24
	FY - 9	FY - 8	FY - 7	FY - 6	FY - 5	FY - 4	FY - 3	FY - 2	FY - 1	FY	LTM

Revenue	46,085	34,943	35,015	36,742	43,545	41,400	44,081	50,739	47,637	46,606	46,606
% Growth	NA	-24.2%	0.2%	4.9%	18.5%	-4.9%	6.5%	15.1%	-6.1%	-2.2%

Cost of Revenue	(20,600)	(11,344)	(11,219)	(13,069)	(16,423)	(15,727)	(17,045)	(18,886)	(19,746)	(20,201)	(20,201)
Gross Profit	25,485	23,599	23,796	23,673	27,122	25,673	27,036	31,853	27,891	26,405	26,405
% Revenue	55.3%	67.5%	68.0%	64.4%	62.3%	62.0%	61.3%	62.8%	58.5%	56.7%	56.7%

Research and Development	(4,274)	(4,405)	(4,504)	(5,170)	(5,308)	(8,531)	(5,721)	(7,404)	(5,630)	(6,387)	(6,387)
Selling and Marketing	(12,074)	(10,831)	(10,811)	(11,052)	(12,336)	(11,620)	(12,274)	(13,546)	(12,572)	(13,003)	(13,003)
General and Admin	(2,176)	(1,855)	(1,878)	(2,186)	(2,465)	(2,266)	(2,257)	(2,490)	(2,142)	(2,184)	(2,184)
Other Inc / (Exp)	(1,270)	(1,216)	(1,613)	(2,297)	(2,765)	(19,208)	(4,154)	(3,064)	(8,518)	(6,261)	(6,261)
Total Operating Exp	(19,794)	(18,307)	(18,806)	(20,705)	(22,874)	(41,625)	(24,406)	(26,504)	(28,862)	(27,835)	(27,835)

Operating Income	5,691	5,292	4,990	2,968	4,248	(15,952)	2,630	5,349	(971)	(1,430)	(1,430)
% Revenue	12.3%	15.1%	14.3%	8.1%	9.8%	-38.5%	6.0%	10.5%	-2.0%	-3.1%	-3.1%

Interest Expense	(455)	(519)	(413)	(1,082)	(1,395)	(1,298)	(584)	(679)	(650)	(904)	(904)
Pre-tax Income	5,236	4,773	4,577	1,886	2,853	(17,250)	2,046	4,670	(1,621)	(2,334)	(2,334)
Earnings of Discontinued Ops.	85	788	4,087	321	1,700	5,074	0	0	0	0	0
Provision for Taxes	(1,223)	(1,017)	(1,329)	(496)	(443)	1,689	(1,024)	(504)	(1,321)	(212)	(212)
Net Income to Company	4,098	4,544	7,335	1,711	4,110	(10,487)	1,022	4,166	(2,942)	(2,546)	(2,546)
% Margin	8.9%	13.0%	20.9%	4.7%	9.4%	-25.3%	2.3%	8.2%	-6.2%	-5.5%	-5.5%

Minority Interest in Earnings	12	(13)	1	(16)	(19)	(8)	(22)	(16)	1	(6)	(6)
Net Income to Stockholders	4,110	4,531	7,336	1,695	4,091	(10,495)	1,000	4,150	(2,941)	(2,552)	(2,552)

Preferred Dividends	0	0	0	0	0	0	0	0	0	0	0
Other Adj.	(85)	(788)	(4,087)	(321)	(1,700)	(5,074)	0	0	0	0	0

Net Income to Common	4,025	3,743	3,249	1,374	2,391	(15,569)	1,000	4,150	(2,941)	(2,552)	(2,552)
% Margin	8.7%	10.7%	9.3%	3.7%	5.5%	-37.6%	2.3%	8.2%	-6.2%	-5.5%	-5.5%

As Reported
Basic EPS (Continuing Ops)	4.87	4.50	3.73	1.46	2.44	(15.85)	1.02	4.22	(2.99)	(2.60)	(2.60)
Diluted EPS (Continuing Ops)	4.87	4.50	3.73	1.46	2.44	(15.85)	1.02	4.22	(2.99)	(2.60)	(2.60)

WA Basic Shares Out.	826.95	832.50	872.11	940.76	981.69	982.42	982.42	982.42	982.42	982.42	982.42
WA Diluted Shares Out.	826.95	832.50	872.11	940.76	981.69	982.42	982.42	982.42	982.42	982.42	982.42

EBITDA, EBIT Reconciliation
EBT, Incl. Unusual Items	5,236	4,773	4,577	1,886	2,853	(17,250)	2,046	4,670	(1,621)	(2,334)	(2,334)
Addback: Net Interest Expense	455	519	413	1,082	1,395	1,298	584	679	650	904	904
Addback: Other Non Operating Expenses, Total	296	214	522	(84)	(215)	210	697	1,513	1,572	1,332	1,332
Addback: Depreciation & Amortization	3,104	2,358	2,120	2,888	3,830	3,058	3,402	3,584	3,532	3,691	3,691
Addback: Restructuring Charges	0	(14)	0	0	0	0	0	0	0	0	0
Addback: Merger / Acquisition Expenses	0	0	210	124	0	0	0	0	0	0	0
Addback: Goodwill Impairment	0	0	0	0	208	2,238	0	734	6,690	3,263	3,263
Addback: Gain (Loss) On Sale Of Invest.	(33)	(4)	(10)	155	(30)	(541)	26	150	11	27	27
Addback: Gain (Loss) On Sale Of Assets	(53)	(42)	(130)	132	0	0	0	0	(152)	(207)	(207)
Addback: Asset Writedown	(52)	(45)	(4)	(4,277)	(439)	(126)	(218)	(1,691)	0	0	0
Addback: In Process R&D Expenses	0	0	0	0	0	0	0	0	0	0	0
Addback: Insurance Settlements	0	0	0	0	0	0	0	0	0	0	0
Addback: Legal Settlements	151	158	258	677	546	13,330	3,689	791	889	282	282
Addback: Other Unusual Items	773	998	1,039	4,562	2,662	7,813	651	2,275	(240)	2,181	2,181
Adjusted EBITDA	9,877	8,915	8,995	7,145	10,810	10,030	10,877	12,705	11,331	9,139	9,139
% Margin	21.4%	25.5%	25.7%	19.4%	24.8%	24.2%	24.7%	25.0%	23.8%	19.6%	19.6%

Adjusted EBIT	6,773	6,557	6,875	4,257	6,980	6,972	7,475	9,121	7,799	5,448	5,448
% Margin	14.7%	18.8%	19.6%	11.6%	16.0%	16.8%	17.0%	18.0%	16.4%	11.7%	11.7%

Adjusted Net Income Reconciliation
Net Income to Company	4,098	4,544	7,335	1,711	4,110	(10,487)	1,022	4,166	(2,942)	(2,546)	(2,546)
Addback: Unusual Items	786	1,051	1,363	1,373	2,947	22,714	4,148	2,259	7,198	5,546	5,546
Less: Tax Benefit of Unusual Items (26%)	(204)	(273)	(354)	(357)	(766)	(5,906)	(1,078)	(587)	(1,871)	(1,442)	(1,442)
Adjusted Net Income	4,680	5,322	8,344	2,727	6,291	6,321	4,092	5,838	2,385	1,558	1,558
% Margin	10.2%	15.2%	23.8%	7.4%	14.4%	15.3%	9.3%	11.5%	5.0%	3.3%	3.3%

載入錯誤

Bayer AG

DB:BAYN

德國 / 保健 / 製藥

10年歷史財務資料